Evidence map›Paper›PMID 35974806›Full record

ReviewJournal of clinical medicine research2022

Kidney Replacement Therapy in Cardiorenal Syndromes.

Daniel Patschan, Kim Drubel, Igor Matyukhin, Benedikt Marahrens, Susann Patschan, Oliver Ritter

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of clinical medicine research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniel PatschanDepartment of Cardiology, Angiology, and Nephrology, Internal Medicine 1, University Hospital of Brandenburg, Medical School of Brandenburg, Brandenburg, Germany.
Kim DrubelDepartment of Cardiology, Angiology, and Nephrology, Internal Medicine 1, University Hospital of Brandenburg, Medical School of Brandenburg, Brandenburg, Germany.
Igor MatyukhinDepartment of Cardiology, Angiology, and Nephrology, Internal Medicine 1, University Hospital of Brandenburg, Medical School of Brandenburg, Brandenburg, Germany.
Benedikt MarahrensDepartment of Cardiology, Angiology, and Nephrology, Internal Medicine 1, University Hospital of Brandenburg, Medical School of Brandenburg, Brandenburg, Germany.
Susann PatschanDepartment of Cardiology, Angiology, and Nephrology, Internal Medicine 1, University Hospital of Brandenburg, Medical School of Brandenburg, Brandenburg, Germany.
Oliver RitterDepartment of Cardiology, Angiology, and Nephrology, Internal Medicine 1, University Hospital of Brandenburg, Medical School of Brandenburg, Brandenburg, Germany.
Klinikum Brandenburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiorenal syndromes (CRS) have increasingly been recognized as distinct disorders that affect the heart and kidneys simultaneously, either with acute or chronic onset. The different types share common pathophysiological characteristics. The concept "cardiorenal" shall emphasize the inter- or even multidisciplinary approach to respective patients. Anticongestive therapy becomes mandatory in many subjects that suffer from CRS. In recent years, the role of dialysis treatment in a broader sense has been investigated in CRS in more detail. We performed a search for studies related to the topic in the following databases: MEDLINE, PROSPERO, and Web of Science. The following keywords were used for reference identification: "CRS", "cardiorenal syndrome", "dialysis", "hemodialysis", "hemofiltration", "renal replacement therapy", "kidney replacement therapy", "peritoneal dialysis", and "aquapheresis". Finally, a total number of 22 studies, partly performed as retrospective cohort studies, and partly designed as prospective investigations, were included. The selected studies evaluated different modes of peritoneal dialysis (PD) or of non-PD procedures including intermittent hemodialysis, continuous procedures, and so-called aquapheresis. Inclusion and outcome parameters were almost not comparable between selected trials. Some studies revealed dialysis as effective, with reasonable tolerability. Particularly so-called "pure" ultrafiltration (e.g., aquapheresis) was associated with higher rates of adverse events. Future studies should be designed in a more homogenous manner, particularly concerning the inclusion criteria, the respective dialysis procedure applied, and endpoints in the short- and long-term.

Indexed as

Cardiorenal syndromeKidney replacement therapyPeritoneal dialysisRefractory hypervolemiaUltrafiltration

Identifiers

PMID35974806
PMCPMC9365664
OpenAlexW4288518662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.